Friday 6 November 2026 Export INCY’s income statement to Excel — free account

Incyte Corporation

INCY Healthcare Biotechnology

Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024.

Revenue: +14.0%
EPS: −277.9%
Free cash flow: −233.0%
Total debt: −10.5%

Quarter to September 2026, against a year earlier

119.22 1.21 +1.03%

Follow INCY

Alert me

Market cap: $24.1B
P/E: 56.3×
Fwd P/E: 55.6×
Dividend yield: —
F-score: 9/9
Altman Z: 8.57
Beneish M: −2.43
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Incyte Corporation 10-Q filed Apr 28, 2026

Fiscal Q1 2026 · Period ended Mar 31, 2026 · Filed Apr 28, 2026 · accepted 4:02 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part II, Item 1A, Risk Factors, against the 10-K filed Feb 10, 2026: 7 added · 1 removed · 24 modified